Predicting toxicity in advanced lung cancer patients treated with platinum-based chemotherapy. (August 2013)

• Record Type: Journal Article
• Authors: Ioannidis, Georgios; Souglakos, John; Georgoulias, Vassilis
• Is Part Of: Lung cancer management. Volume 2:Number 4(2013)
• Page Start: 281
• Page End: 293
• Publication Date: 2013-08
• Subjects: Lungs -- Cancer -- Periodicals; 616.99424
• DOI: 10.2217/lmt.13.26
• Languages: English
• ISSNs: 1758-1966

Abstract

SUMMARY Platinum-based chemotherapy is currently the state-of-the-art first-line cytotoxic treatment of advanced-stage small-cell lung cancers and non-small-cell lung cancers, but at the cost of potentially severe toxicity. As platinum-related adverse events may impede the success of palliative chemotherapy, while negatively affecting the patients' quality of life, treatment strategies should aim at optimizing the toxicity:benefit ratio. The identification and application of clinical and laboratory biomarkers, including pharamacogenetic tools, for reliably predicting toxicity in this setting would significantly contribute to such a customized approach. This is a comprehensive overview of the toxicity-prediction factors with the most potential, including ethnicity, age, gender, performance status, comorbidity and nutrition, as well as molecular biomarkers, such as germline genetic polymorphisms.